The price of Zerbaxa is listed at 60,098 won

Ryaltris 18ml is priced at 6,197 won

It passed the review committee for two new drugs and applied insurance benefits on October 1st

Zerbaxa, called the next-generation antibiotic for MSD Korea, will be listed at 60,098 won per vial as of the 1st of next month.

 

Yuhan Corporation's allergic rhinitis treatment Ryaltris nasal spray 18ml is listed at 6,197 won and Ryaltris nasal spray 31ml is listed at12,396 won, respectively.

 

The Ministry of Health and Welfare held a health insurance policy review committee today (29th) and announced that it was approved for the revision of the "drug benefit list and upper limit table" for a total of three new drugs.

 

These drugs will be listed on the drug benefit list as of October 1 and sold at insurance prices.

 

◆Zerbaxa = This drug is an antibacterial agent used to treat complex intra-abdominal infections and complex urinary tract infections and was approved by the Ministry of Food and Drug Safety as of April 7, 2017.

 

The company applied for insurance registration in early November last year and applied for insurance registration with the HIRA in November of the same year.

 

The HIRA submitted it to the Drug Benefit Evaluation Committee in June this year for deliberation.

 

At the time, the committee confirmed that clinical usefulness was inferior to that of the control group, and judged that the company's price was more cost-effective than the Japanese drug price, which is the lowest A7.

 

Among the A7 countries, it was listed in the U.S., Japan, Italy, and the U.K., and the average adjustment price was 108,383 won per bottle.

 

Since then, the Ministry of Health and Welfare has negotiated drug prices with the NHIS from June to August this year and decided on the expected amount of claims.

 

The NHIS and the company signed an Expenditure cap RSA contract to refund the amount to the NHIS if it exceeds a certain amount (cap).

 

The price was agreed to be 60,098 won per bottle, down 6.44% from the price passed by the evaluation committee, considering the number of patients who are eligible for more PE drugs such as anticancer drugs and rare disease treatments.

 

◆Ryaltris nasal spray = This drug, a treatment for seasonal allergic rhinitis, was approved by the Ministry of Food and Drug Safety as of June 22, 2020.

 

The company applied for the HIRA insurance registration more than a year later on July 30, 2021.

 

The HIRA introduced the drug and conducted deliberation on January 13 this year.

 

At the time, the evaluation committee judged that it was more effective in relieving symptoms than a single drug in terms of clinical needs and that it was cost-effective as the company accepted less than 90% of the weighted average price of alternative drugs.

 

It is listed in the UK and Italy among the A7 countries, and the adjusted average price is 16,308 won per 240 doses.

 

In February, the company moved to the industrial complex to negotiate the expected amount of claims.

 

Initially, the two sides conducted and completed negotiations for two months, but the application for registration was made after confirming the possibility of normal supply due to delayed imports due to COVID-19.

 

It predicted that no additional finances would be required because alternative drugs such as Motesone plus Nasal Spray or Dylastine existed.

 

The insurance price is 6,197 won for Ryaltris 18mL and 12,396 won for Ryaltris 31mL.